Assort Health, which is developing voice AI agents for healthcare to manage patient phone calls, raised a $22M Series A co-led by First Round and Chemistry
Assort Health cofounders Jeff Liu and Jon Wang. — Assort Health — Jon Wang and Jeff Liu met dozens of prospective cofounders—until they met each other.
Context & Ripple Effects
This early round became the base for Assort Health’s subsequent financing arc: the company later raised a $76M Series B and then a $120M Series C at a $1.2B valuation.
The company sits in a growing cluster of healthcare AI vendors focused on patient communications, alongside newer phone-answering entrants such as Prosper AI’s patient-call platform and workflow-oriented assistants for pharmacies.
First-order effects
- Assort Health gains $22M to develop and deploy voice AI agents that manage patient phone calls for healthcare providers.
- First Round and Chemistry become financial backers of Assort’s effort to automate a provider-facing communications workflow.
Second-order effects
- Healthcare providers evaluating patient-call automation gain another funded vendor option, while rival AI communications companies face a better-capitalized competitor.
- The round helps validate patient communications as a distinct healthcare-AI buying category, adjacent to broader patient messaging and administrative-workflow tools.
Third-order effects
- If follow-on funding and new entrants persist, patient access and communications could become a specialized AI software layer rather than a feature embedded only in wider healthcare systems.
- Capital may increasingly concentrate behind vendors that can expand from answering calls into more healthcare workflows, though the coverage does not establish which product scope will prevail.
The trend: Healthcare AI investment is moving toward automation of patient-facing administrative interactions, with voice agents emerging as a focused product category.